Previous 10 | Next 10 |
Study found 1 in 5 patients was positive for a genetic cause of CKD, 1 in 2 positive patients received a new or reclassified diagnosis, and 1 in 3 positive patients had a change in treatment plan Diagnostic yield and utility exceed clinical precedents for implementation of routine genetic...
2023-10-29 17:28:12 ET More on Guardant Health, Natera, etc. Natera: Cash Burn Remains A Concern Guardant Health: Peeling Back Economic Layers, Compressed Market Values Appear Justified Pacific Biosciences: Looks Appealing In The Fast-Growing Long-Read Sequencing Mar...
2023-10-25 14:17:58 ET Summary Today, we circle back on Natera, Inc., a fast-growing diagnostic testing concern. The company continues to rack up impressive sales growth, but its cash burn remains a primary concern. With Natera, Inc. stock down some 30% from recent highs, is n...
Builds on published evidence with twice as many patients and disease-free survival data extended to 24 months Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced updated data from the GALAXY arm of the CIRCULATE-Japan trial further showcasing the a...
NATERA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA NATERA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Di...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its third quarter ended September 30, 2023, after the market close on Nov. 8, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has been named by U.S. News & World Report as one of the best companies to work for in healthcare. Natera was ranked among 349 companies across 20 fields of work on factors contributing to job...
2023-10-17 09:15:48 ET Palm Beach, FL – October 17, 2023 – FinancialNewsMedia.com News Commentary – Multiple myeloma is a type of cancer that affects plasma cells, which are a type of white blood cell that produces antibodies to fight infections. The US mult...
Presentations include largest analysis from the GALAXY study in colorectal cancer with updated 24-month disease-free survival data, and expanded Signatera readout in rectal cancer Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will present ...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Natera, Inc. (NasdaqGS: NTRA). On March 14, 2022, a jury found that the Company intentionally...
News, Short Squeeze, Breakout and More Instantly...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that members of its leadership team will present at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, Aug. 14 at 12:30 pm ET | 9:30 am PT in Boston, MA. A live webcast and audio archive of...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2024, after the market close on Aug. 8, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...